z-logo
Premium
Bendamustine plus alemtuzumab is safe and feasible treatment for fludarabine refractory chronic lymphocytic leukaemia ( CLL )
Author(s) -
Hill Brian T.,
Caimi Paolo,
KindwallKeller Tammy,
Habecker Becky,
Kalaycio Matt
Publication year - 2014
Publication title -
british journal of haematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.907
H-Index - 186
eISSN - 1365-2141
pISSN - 0007-1048
DOI - 10.1111/bjh.12604
Subject(s) - bendamustine , alemtuzumab , fludarabine , medicine , chronic lymphocytic leukemia , chlorambucil , neutropenia , purine analogue , oncology , rituximab , combination therapy , chemotherapy , gastroenterology , cyclophosphamide , leukemia , transplantation , lymphoma , purine , biochemistry , chemistry , enzyme

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here
Accelerating Research

Address

John Eccles House
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom